Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
Sung Han KimDong-Eun LeeJae Young JoungHo Kyung SeoKang Hyun LeeJin-Soo ChungPublished in: Investigative and clinical urology (2020)
TT significantly prolonged PFS compared with IT, whereas long-term survival was not significantly different in intermediate-risk mRCC patients.